Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche invests in biological cancer medicines

Roche invests in biological cancer medicines

20th January 2010

Roche revealed this week that it will invest 190 million Swiss francs (112.18 million pounds) into centres working towards the development of a device that will allow patients to self-administer biological cancer therapies.

The infusion-free product delivers Herceptin (trastuzumab), a formulation developed with Halozyme Therapeutics’ Enhanze technology, to patients being treated for the disease.

This allows for the injection of larger volumes of medicines into the tissue under the skin, meaning that therapies currently administered by infusion could be self-administered using a subcutaneous injection.

A phase III trial examining the use of Herceptin is currently being carried out.

Pat Yang, head of Roche’s global technical operations, stated: “This innovative formulation and the associated new device are designed to simplify patients’ lives. There is also hope that patients will experience fewer infusion reactions due to the slower absorption.”

Last week, Roche revealed that the Food and Drug Administration has approved its rheumatoid arthritis therapy ACTEMRA (tocilizumab).

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.